Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arbutus Biopharma Corp ABUS

Healthcare Biotechnology
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran... see more

Recent & Breaking News (NDAQ:ABUS)

Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update

GlobeNewswire February 22, 2021

Arbutus Announces 2021 Corporate Objectives and Provides Financial Update

GlobeNewswire January 25, 2021

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

GlobeNewswire January 4, 2021

Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects

GlobeNewswire December 10, 2020

Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects

GlobeNewswire November 16, 2020

Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience(TM), The American Association for the Study of Liver Diseases Meeting

GlobeNewswire November 15, 2020

Arbutus to Present at Jefferies Virtual London Healthcare Conference

GlobeNewswire November 10, 2020

Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2020

Arbutus to Report Third Quarter 2020 Financial Results and Provide Corporate Update

GlobeNewswire October 29, 2020

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

GlobeNewswire October 13, 2020

Arbutus to Participate in Virtual Fireside Chat at Chardan's 4th Annual Genetic Medicines Conference

GlobeNewswire September 28, 2020

Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg

GlobeNewswire September 15, 2020

Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference

GlobeNewswire September 9, 2020

Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection

GlobeNewswire August 27, 2020

Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2020

Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 5, 2020

Arbutus to Report Second Quarter 2020 Financial Results

GlobeNewswire July 29, 2020

Arbutus to Present at Jefferies Virtual Healthcare Conference

GlobeNewswire May 27, 2020

Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg

GlobeNewswire May 18, 2020

Arbutus to Present at UBS Virtual Global Healthcare Conference

GlobeNewswire May 12, 2020